| Bioactivity | SARS-CoV-2 3CLpro-IN-18 (Compound 3C) is a covalent SARS-CoV-2 3CLpro inhibitor (IC50s: 0.478 μM). SARS-CoV-2 3CLpro-IN-18 inhibits SARS-CoV-2 in Vero E6 cells (EC50= 2.499 μM) with low cytotoxicity (CC50 > 200 μM)[1]. |
| Target | 0.478 μM (SARS-CoV-2 3CLpro) |
| Name | SARS-CoV-2 3CLpro-IN-18 |
| Formula | C17H13ClN2OS |
| Molar Mass | 328.82 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Ren P, et al. Discovery and Mechanism Study of SARS-CoV-2 3C-like Protease Inhibitors with a New Reactive Group. J Med Chem. 2023 Aug 18. |
SARS-CoV-2 3CLpro-IN-18
CAS: F: C17H13ClN2OS W: 328.82
SARS-CoV-2 3CLpro-IN-18 (Compound 3C) is a covalent SARS-CoV-2 3CLpro inhibitor (IC50s: 0.478 μM). SARS-CoV-2 3CLpro-IN
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.